Analyst Says Obagi (OMPI) Could Soon See Offers from 'Multiple Suitors'

Article Stock Quotes (4) Comments (0)

Investors are dipping a toe into shares of Obagi Medical Products (Nasdaq: OMPI) Monday morning as Cantor Fitzgerald's Irina Rivkind said the company could be attractive to "multiple suitors." The stock is up about 2 percent at last check.

The analyst named Valeant (NYSE: VRX), Medicis (NYSE: MRX) and Allergan (NYSE: AGN) as potential interested companies, and also said a pure-play cosmetics company could also get involved.

Rivkind called Obagi attractive given its "brand recognition" and reputation for efficacy. The analyst also pointed to the company's pristine balance sheet and "healthy" growth.

Track all the market-moving analyst calls on shares of Obagi with our Analyst Ratings page.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Lazard Capital Downgrades Warner Chilcott (WCRX), Says Deal Could Fall Through
• Goldman Sachs Upgrades Meritor (MTOR) to Buy
• Best Buy (BBY) May Show Progress on Earnings Front, UBS Remains Neutral

Create E-mail Alert Related Categories

Analyst Comments, Rumors

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?